These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 30019681)

  • 61. Mucocutaneous manifestations in systemic amyloidosis A retrospective analytical study in a tertiary care center.
    Flores-Bozo LR; Echevarría-Keel J; Domínguez-Cherit J; Esquivel-Pedraza L; Méndez-Flores S
    Int J Dermatol; 2019 Sep; 58(9):1062-1068. PubMed ID: 30941743
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The treatment of paraprotein-related kidney disease.
    Hutchison CA; Xiong F; Mollee P
    Curr Opin Nephrol Hypertens; 2017 Nov; 26(6):477-483. PubMed ID: 28885307
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immunophenotypic analysis of abnormal plasma cell clones in bone marrow of primary systemic light chain amyloidosis patients.
    Hu Y; Wang M; Chen Y; Chen X; Fang F; Liu S; Zhang Y; Wu X; Zhu P
    Chin Med J (Engl); 2014; 127(15):2765-70. PubMed ID: 25146610
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Primary systemic amyloidosis associated with multiple myeloma: a case report and review of the literature.
    Mason AR; Rackoff EM; Pollack RB
    Cutis; 2007 Sep; 80(3):193-200. PubMed ID: 17956007
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.
    Wang Y; Xu L; Liu Y; Hu Y; Shi Q; Jin L; Yang L; Wang P; Zhang K; Huang X; Ge Q; Lu J
    Int J Hematol; 2021 Feb; 113(2):231-242. PubMed ID: 33040275
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome.
    Tovar N; Rodríguez-Lobato LG; Cibeira MT; Magnano L; Isola I; Rosiñol L; Bladé J; Fernández de Larrea C
    Amyloid; 2018 Jun; 25(2):79-85. PubMed ID: 29482381
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Simultaneous multiple myeloma and giant cell arteritis without systemic amyloidosis].
    Finn BC; Young P; Silva ED; Bruetman JE; Bottaro FJ; Venditti JE; Shanley CM; Ceresetto J; Bullorsky E
    Medicina (B Aires); 2006; 66(6):555-7. PubMed ID: 17240628
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Obstructive cardiomyopathy, caused by amyloidosis, associated with bone marrow myeloma].
    Rusznák M; Jakó J; Francz M; Babicz T
    Orv Hetil; 1993 May; 134(19):1033-6. PubMed ID: 8493032
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evidence of both von Willebrand factor deposition and factor V deposition onto AL amyloid as the cause of a severe bleeding diathesis.
    Harrison JS; Frazier SR; McConnell DD; Yasar SJ; Melnyk N; Salaru G
    Blood Coagul Fibrinolysis; 2017 Jun; 28(4):342-347. PubMed ID: 27676646
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [An unusual presentation of Amyloidosis AL].
    Zito A; De Pascalis A; Ria P; Armeni A; D'Amelio A; Napoli M
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786185
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The blue man: a novel cutaneous manifestation of systemic amyloidosis.
    Campbell M; Rosenthal A; Kundranda M; Pickert A; Dicaudo D; Dogan A; Mikhael J
    Amyloid; 2011 Sep; 18(3):156-9. PubMed ID: 21506660
    [TBL] [Abstract][Full Text] [Related]  

  • 72. First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma.
    Oliver-Caldes A; Jiménez R; Español-Rego M; Cibeira MT; Ortiz-Maldonado V; Quintana LF; Castillo P; Guijarro F; Tovar N; Montoro M; Benitez-Ribas D; Bataller A; González-Navarro EA; Cid J; Lozano M; Perez-Amill L; Martin-Antonio B; Mena MP; Moreno DF; Rodríguez-Lobato LG; Campistol JM; Calvo G; Bladé J; Rosiñol L; Juan M; Pascal M; Urbano-Ispizua A; Fernández de Larrea C
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34876408
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
    Zhang C; Huang X; Li J
    Blood Rev; 2017 Jul; 31(4):261-270. PubMed ID: 28336182
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Lingual liability: macroglossia and dyspnoea as the harbinger of systemic AL (light-chain) cardiac amyloidosis.
    Williams MU; Murphy CE; Gore RS; Fentanes E
    BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30580294
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Traumatic Avulsion of Upper Eyelid Skin Following Surgery in a Patient With Multiple Myeloma and Amyloid Light-chain Amyloidosis.
    Ergün SS; Zengin SÜ; Ünal M; Yildiz P
    Wound Manag Prev; 2020 Sep; 66(9):16-19. PubMed ID: 32903200
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Bone disease as the first manifestation of systemic AL-amyloidosis].
    Mendeleeva LP; Rekhtina IG; Kovrigina AM; Kostina IE; Khyshova VA; Arytyunyan NK; Mamonov WE; Savthenko VG
    Ter Arkh; 2020 Sep; 92(7):85-89. PubMed ID: 33346449
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunoglobulin synthesis in primary and myeloma amyloidosis.
    Preud'homme JL; Ganeval D; Grünfeld JP; Striker L; Brouet JC
    Clin Exp Immunol; 1988 Sep; 73(3):389-94. PubMed ID: 3145161
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development.
    Alameda D; Goicoechea I; Vicari M; Arriazu E; Nevone A; Rodriguez S; Lasa M; Puig N; Cedena MT; Alignani D; Garate S; Lara-Astiaso D; Vilas-Zornoza A; Sarvide S; Ocio EM; Lecumberri R; Garcia de Coca A; Labrador J; Gonzalez ME; Palomera L; Gironella M; Cabañas V; Casanova M; Oriol A; Krsnik I; Perez-Montaña A; de la Rubia J; de la Puerta JE; de Arriba F; Fazio VM; Martinez-Lopez J; Lahuerta JJ; Mateos MV; Odero MD; Prosper F; Weiner A; Amit I; Nuvolone M; San Miguel JF; Paiva B
    Blood; 2021 Oct; 138(17):1583-1589. PubMed ID: 34133718
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in both AA amyloidosis associated with rheumatoid arthritis and AL amyloidosis.
    Kuroda T; Tanabe N; Hasegawa E; Wakamatsu A; Nozawa Y; Sato H; Nakatsue T; Wada Y; Ito Y; Imai N; Ueno M; Nakano M; Narita I
    Amyloid; 2017 Jun; 24(2):123-130. PubMed ID: 28613962
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Massive systemic amyloidosis associated with light-chain deposition disease.
    Troussard X; Hurault de Ligny B; Gallet B; Ganeval D; Mandard JC; Ryckelynck JP; Leporrier M
    Nephron; 1989; 52(2):139-43. PubMed ID: 2500613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.